Ampyra is called Fampyra in Europe.
Information about Ampyra (Dalfampridine)
Ampyra, with the active ingredient dalfampridine, is primarily prescribed to improve walking ability in individuals with multiple sclerosis (MS). It works by enhancing nerve conduction in the central nervous system, thereby potentially improving walking speed and ability.
The key active ingredient in Ampyra is dalfampridine, also known as fampridine, which is a potassium channel blocker. It works by blocking certain potassium channels in nerve cells, which may help improve nerve conduction.
Product Highlights
- Ampyra is known for its targeted action in improving mobility specifically in MS patients.
- It is formulated to address the specific neurological challenges associated with the disease, offering a potential improvement in quality of life by enhancing mobility.
Key Ingredients
Key Benefits
- Helps improve walking speed and ability in individuals with MS.
- Addresses a specific symptom of MS, enhancing daily functioning.
- Targets nerve conduction deficits, potentially improving overall mobility.
Direction For Use
- Typically, Ampyra is taken as a 10 mg tablet twice daily, with a 12-hour interval between doses.
- It should be taken whole and not crushed, divided, or chewed.
- Continuous use is necessary to maintain benefits; however, effectiveness may vary between individuals.
Safety Concern
- Dalfampridine may increase the risk of seizures, particularly in individuals with a history of seizures or certain kidney disorders.
- It's important to discuss all medications and supplements with a healthcare provider to avoid potential interactions.
- Regular monitoring of kidney function is recommended due to the excretion of dalfampridine through the kidneys.
Avoid Taking Ampyra (Dalfampridine) If:
- If you have a history of seizures or are at risk of seizures.
- If you have severe kidney impairment, as dalfampridine is excreted through the kidneys.
- If you have experienced an allergic reaction to dalfampridine or any of its components.
